Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
107 hedge funds and large institutions have $674M invested in Kezar Life Sciences in 2021 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 8 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
241% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $1.59M
178% more capital invested
Capital invested by funds: $243M → $674M (+$431M)
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
41% more funds holding
Funds holding: 76 → 107 (+31)
2.39% more ownership
Funds ownership: 5.83% → 8.22% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$33.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.2M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$11.5M |
| 5 |
Holocene Advisors
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$29.9M |
| 2 |
O
OrbiMed
New York
|
-$9.94M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.54M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$3.05M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$2.39M |
KZR Hedge Fund Activity: Q4 2021 in Review
107 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2021, worth a combined $674M — up 178% from $243M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new KZR positions and 8 closed out — a net gain of 31 holders — while 34 added to existing stakes and 22 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $33.5M. The largest seller was Logos Global Management, cutting an estimated $29.9M.
- 107 institutional investors held Kezar Life Sciences (KZR) as of Q4 2021, up from 76 in Q3 2021.
- Funds reported $674M of Kezar Life Sciences stock for Q4 2021, up 178% quarter-over-quarter.
- 39 funds opened new Kezar Life Sciences positions in Q4 2021 and 8 closed out, a net change of +31 holders.
- The largest Kezar Life Sciences buyer in Q4 2021 was Avidity Partners Management, an estimated $33.5M added.
- The largest Kezar Life Sciences seller in Q4 2021 was Logos Global Management, an estimated $29.9M sold.
Based on aggregated 13F filings for Q4 2021.